AzTrials
AzTrials

Hematologic DiseasesNCT05541835

Hematological Abnormalities in Children

An observational study of Hematologic Diseases, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

the aim of the study is to determine Hematological abnormalities in Congenital Cyanotic Heart Disease Read more about this study

Who is it for?
Ages 1 year to 18 yearsHealthy volunteers can take part
Conditions the study is for
Hematologic Diseases
What is being tested?
sampling
How many people
30 participants
Where
No sites listed yet
Study dates
20 Mar 2023to 20 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: All childern with Cyanotic Congenital heart disease admitted to the pediatric cardiology unit of Assiut University Hospitals over a period of one year

Who may be able to join

  • All children.
  • congenital cyanotic heart disease

Who cannot join

  • other congenital heart disease.
  • other congenital anomalies.
  • other chronic disease.
  • post-operative patient.

Trial locations and contacts

No sites are listed yet.

mamoud abdelshkour, master contact

01140062035

midoabdelshakour321@gmail.com

About this study

Official title: Hematological Abnormalities In Children With Congenital Cyanotic Heart Disease Attending Assiut University Hospitals: A Prospective Hospital- Based Study.

the aim of the study is to determine Hematological abnormalities in Congenital Cyanotic Heart Disease

Read the detailed description

Congenital heart defects are the most common developmental anomaly and are the commonest noninfectious causes of mortality in newborns; they affect up 1000 infants and in most cases the cause is unknown . Erythrocytosis, thrombocytopenia, platelets function defects, coagulation factors deficiencies are the main hematologic disorders in patients with cyanotic congenital heart disease .The hemorrhagic tendency was initially attributed to an increase in tissue vascularity, but co-existing hemostatic defects were subsequently identified and attributed to thrombocytopenia, shortened platelet survival, and deficient von Willebrand multimers .

In patients , platelets are shown to have both qualitative and quantitative abnormalities.However, there are conflicting data as regards the etiology of thrombocytopenia in congenital cyanotic heart disease . significant association has been reported between thrombocytopenia and a high hematocrit in cyanotic patients and multiple etiologies has been suggested including chronic compensated disseminated intravascular coagulation (DIC), reduce synthesis of clot factors and/or deranged platelet aggregation. Immature reticulated platelets represent the youngest platelets released into the circulation by regenerated marrow megakaryocyte and are the analogue of the red cell reticulocyte .The rate of platelet turnover can be evaluated by the relationship between the percent of reticulated platelets and the platelet count.

Erythrocytosis is an isolated increase in the number of red blood cells. Primary erythrocytosis is an increased red cell mass which surfaces in the absence of a definable stimulus, whereas secondary erythrocytosis refers to an isolated increase in the red cell mass in response to such stimulus as low systemic arterial oxygen saturation in the context of cyanotic congenital heart disease. Polycythemia could often be beneficial. Yet, it poses certain risks to the microcirculation. This is mainly because the capillary diameter is significantly smaller than the red cell diameter and this mismatch could cause viscosity

To increase at the capillary level. Patients with cyanotic heart disease may have an acceptable quality of life. However, they are invariably prone to several complications. For instance, hyperviscosity, hyperuricemia (mainly due to age-related impairment of uric acid excretion in adults), thrombocytopenia (decreased level of platelet production), blood clotting abnormalities (reduced synthesis of clotting factors and/or deranged platelet aggregation), cerebral abscess, cerebral embolism and endocarditis .

Being tested
sampling
Medical subject headings
Hematologic Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • samplingDiagnostic test

    venous sampling of patient

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hematological Abnormalities In ChilCongenital congenital Cyanotic Heart Disease

    Determine hematological abnormality

    Measured: Baseline

Secondary outcomes (1)
  1. Children with Congenital Cyanotic Heart Disease

    To change morbidity and mortality, number of death in children with congenital cyanotic heart disease.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2022
  2. Study start20 Mar 2023 (estimated)
  3. Primary completion20 Nov 2023 (estimated)
  4. Study completion20 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05541835
Sponsor's protocol ID
Hematological Abnormalities
Status last verified
Mar 2023
First submitted
25 Jun 2022
Last updated
31 Mar 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Hematologic Diseases, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 31 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact mamoud abdelshkour, master (01140062035, midoabdelshakour321@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hematological Abnormalities In ChilCongenital congenital Cyanotic Heart Disease (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in